Power supply device for an electronic unit of a drug delivery device - Patents.com
The power supply device with a rechargeable energy reservoir and separate charging interface addresses miniaturization and charging challenges in drug delivery devices, enhancing user safety and operability by allowing compact design and easy charging.
Patent Information
- Application Number
- JP2024526565
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-03
- Filing Date
- 2022-11-01
- Publication Date
- 2024-11-13
AI Technical Summary
Existing drug delivery devices with integrated electronic units face challenges in miniaturization due to the space required for batteries and difficulty in charging non-accessible power sources, complicating user safety and operability.
A power supply device with a rechargeable energy reservoir that includes a power supply interface to charge the electronic unit and a charging interface for external power connection, allowing for miniaturization and easy charging without overlapping processes.
The solution enables compact design and easy charging of electronic units in drug delivery devices, improving user safety and operability by decoupling charging processes and providing flexible power management.
Smart Images

Figure 2024542088000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a power supply device for an electronic unit of a drug delivery device. In another aspect, the present disclosure relates to a drug delivery device equipped with such a power supply device. [Background technology]
[0002] Drug delivery devices for setting and dispensing single or multiple doses of liquid medicaments are well known per se in the art. In general, such devices have a purpose substantially similar to that of a conventional syringe.
[0003] Drug delivery devices such as pen injectors, e.g. injection devices and needle based injection system (NIS) devices, must meet several requirements specific to the user. For example, in the case of patients suffering from chronic diseases such as diabetes, the patient may be physically frail and may have poor eyesight. Therefore, a suitable drug delivery device, especially intended for home medication, must be robust in construction and easy to use. Furthermore, the operation and overall handling of the device and its components must be straightforward and easily understandable. Such an injection device must provide for the setting and subsequent dispensing of doses of a variable size drug. Furthermore, the dose dispensing procedure along with the dose setting must be easy to operate and clear.
[0004] Patients suffering from certain diseases may need to have a measured amount of medication injected via a syringe pen or infused via a pump.
[0005] Some drug delivery or injection devices allow for the selection of variable sized doses of medication and for the injection of preset doses. Other injection devices allow for the setting and dispensing of a fixed dose, where the amount of medication to be injected according to a given prescription schedule is always the same and does not change or cannot be altered over time.
[0006] Needle-based injections performed using various injection devices are becoming increasingly associated with measuring and logging data regarding the amount of medication set or dispensed or injected on a particular day or time. To this end, injection devices can be provided with electronic circuitry that provides for data collection and / or data logging as well as communication of the medication-related data collected or measured.
[0007] The electronic circuit or electronic unit may be provided by an auxiliary or add-on device configured to be releasably attached to the injection device and operable to log injection-related data during use of the injection device. Such an electronic circuit or electronic unit may also be implemented or incorporated in the injection device itself. Furthermore, the data logging electronic circuit may also be provided with a communication interface to transmit previously stored injection-related data to an external electronic device for further data processing.
[0008] Since electronic circuits consume power, such electronic units are usually equipped with a power source such as a battery. The batteries of such electronic circuits require respective construction space, which makes it difficult to further miniaturize such electronic units. In handheld or portable drug delivery devices, construction space is quite limited, so it is particularly targeted to further miniaturize the battery and / or electronic unit integrated or attached to the drug delivery device.
[0009] Generally, the power source of the electronic unit may include a rechargeable battery, however, charging such a battery, which is not directly accessible from outside the drug delivery device, may also be quite difficult. Summary of the Invention [Problem to be solved by the invention]
[0010] It is therefore an object of the present disclosure to provide an improvement regarding electrical energy supply for e.g. an electronic unit of a portable drug delivery device, which should further improve and simplify the operation of the drug delivery device as well as the safety of the patient for the user. [Means for solving the problem]
[0011] In one embodiment, the present disclosure relates to a power supply device for an electronic unit of a drug delivery device. The power supply device includes a body extending along a longitudinal direction and including a distal end and a proximal end. The distal end and the proximal end are opposite ends or end sections of the body and thus the power supply device. The power supply device further includes a rechargeable energy reservoir disposed in or on the body. The power supply device further includes a power supply interface electrically connected to the rechargeable energy reservoir. The power supply interface is configured to electrically couple with the electrical interface of the drug delivery device.
[0012] The electrical interface of the drug delivery device is electrically connected to the electronic unit of the drug delivery device, where the power supply interface of the power supply device is operable or configured to transfer electrical energy from the rechargeable energy reservoir to the electronic unit of the drug delivery device via the electrical interface. The power supply device further includes a charging interface electrically connected to the rechargeable energy reservoir. The charging interface is operable to connect to an external power source to charge the rechargeable energy reservoir.
[0013] Thus, the power supply device disclosed herein includes a rechargeable energy reservoir that is primarily responsible for charging and / or providing electrical energy to the electronic unit of the drug delivery device. Typically, the rechargeable energy reservoir is operable to charge a local electrical energy reservoir, e.g., a battery, of the electronic unit. Thus, the provision of electrical energy to the drug delivery device by the power supply interface can be performed in conjunction with charging the local battery of the electronic unit or the drug delivery device. In this way, the rechargeable energy reservoir of the power supply device acts and behaves as a charger for the battery of the electronic unit of the drug delivery device.
[0014] The rechargeable energy reservoir of the power supply device itself is also rechargeable. In this way, and because the power supply device is equipped with a rechargeable energy reservoir, for example to charge the battery of the electronic unit of the drug delivery device, the storage capacity of the rechargeable energy reservoir can be reduced, and thus the geometric dimensions of the rechargeable energy reservoir and the power supply device itself can be further reduced. This has the advantage of miniaturizing the power supply device and providing an attractive solution for sophisticated users to actually implement the power supply device.
[0015] In some examples, the power supply device can be integrated into a component of the drug delivery device. Reducing the storage capacity of the rechargeable energy reservoir allows for a compact design of each of the power supply devices. This allows for the power supply device to be smoothly integrated into, for example, a removable component of the drug delivery device.
[0016] In another example, the power supply device provides a kind of power bank for providing electrical energy to the electronic unit of the drug delivery device on demand. The power supply device is specifically and selectively available or activatable when a local battery mounted on the electronic unit is depleted. And, the local battery of the electronic unit, which is of a rechargeable type, can be charged by establishing an electrical coupling or connection between the power supply interface of the power supply device and the electronic unit of the drug delivery device.
[0017] After such charging procedures are performed many times, the rechargeable energy reservoir of the power supply device may also be depleted, so the charging interface of the power supply device can now be used to connect the power supply device to an external power source to charge the rechargeable energy reservoir.
[0018] According to another example, the charging interface includes a power connector. The power connector can be configured to establish or contribute to a galvanic connection with a complementary shaped power connector of an external power source. The power connector of the charging interface can be implemented according to a well-established power connector standard. The power connector may include a USB connector or any other standardized power connector.
[0019] In some examples, the charging interface, and therefore the power connector, includes one of a plug and a socket that removably connects to a complementarily shaped mating socket or plug of the external power source. In this manner, a fairly easy and straightforward method of charging or recharging the rechargeable energy reservoir of the power source can be provided.
[0020] According to a further example, the charging interface includes an inductive coupler configured to inductively couple with a complementary shaped mating inductive coupler of the external power source, where charging of the rechargeable energy reservoir can be performed or carried out based on a conductive, and thus contactless, electrical coupling between the inductive coupler of the power supply device and the complementary or corresponding mating inductive coupler of the external power source.
[0021] The inductive coupler enables wireless charging and can be provided in place of one of the plug and socket of the charging interface. The inductive coupler allows the charging interface of the power supply device to be socket and plug-free. The wireless charging interface of the power supply device can enable and support a rather attractive design where the power supply device has neither a plug nor a socket of a power connector.
[0022] According to a further example, the rechargeable energy reservoir is disposed inside the body. The power interface is disposed at or extends to the proximal end of the body. The charging interface is disposed at the distal end. Disposing the power interface and the charging interface at the longitudinally opposite ends of the rechargeable energy reservoir is beneficial in many aspects. For example, the power interface of the power supply device may be electrically coupled or remain electrically coupled with the electrical interface of the drug delivery device, and at the same time, the charging interface may be electrically coupled with an external power source. In this way, direct charging or recharging of the local battery of the electronic unit can be provided, where the rechargeable energy reservoir only acts as a buffer for electrical energy.
[0023] Furthermore, by having the power supply interface and the charging interface at opposite ends of the body, the respective interfaces do not overlap spatially, whereby the power supply interface can be connected to the electronic unit independently of the connection of the charging interface to an external power source. In this way, the charging process of the rechargeable energy reservoir can be decoupled from the charging process of the local battery of the electronic unit, which is supplied by the rechargeable energy reservoir. In this way, the time scales for the respective charging processes, i.e. for a first charging process in which the electronic unit is charged with or supplied with electrical energy from the rechargeable energy reservoir and a second charging process in which the rechargeable energy reservoir itself is supplied with electrical energy from an external power source via the charging interface, can be implemented almost completely independent of each other. In this way, the flexibility in using the power supply device can be improved, and the user acceptance of such a power supply device can be improved.
[0024] According to a further example, the body of the power supply device includes a mechanical mating interface at a proximal end for removably fastening the body to a complementary shaped mechanical interface of the drug delivery device, Mechanical fastening of the body of the power supply device to a mechanical mating interface, for example provided on or in the housing of the drug delivery device, is of utility for supplying electrical energy to an electronic unit of the drug delivery device.
[0025] The body of the power supply device can be interfastened with the drug delivery device to provide a durable electrical connection or coupling between the power supply interface of the power supply device and the electrical interface of the drug delivery device.
[0026] According to a further example, the mechanical mating interface of the body of the power supply device includes a mating fastener that removably engages with a complementary shaped fastener provided on the mechanical interface of the drug delivery device. In some examples, the fastener and the mating fastener form one of a snap-fit connection, a clip joint, a bayonet joint, or a threaded joint. The mating fastener engages with the fastener of the drug delivery device to maintain the power supply device, at least its body, in a stationary charging position relative to the drug delivery device.
[0027] Typically, the power supply device is a portable device. The charging interface can be electrically connected to an external power source regardless of the respective configuration of the power interface. The charging interface can be connected to the external power source while the power interface is disconnected from the electrical interface of the drug delivery device. In another example, the charging interface can be connected to the external power source while the power interface is connected to the electrical interface of the drug delivery device.
[0028] According to a further example, the body of the power supply device includes a sidewall that limits the extent of the receptacle. The receptacle may be open toward the proximal direction and may be shaped and sized to receive at least a portion of the drug delivery device. In some examples, the power supply device may be integrated into the housing or into a housing portion of the drug delivery device. The receptacle may be sized and shaped to receive a portion of the drug delivery device, for example a distal portion. When the drug delivery device is implemented as a handheld injection device, such as an injection pen, the receptacle of the body of the power supply device may be sized and configured to receive a cartridge or container holder portion of a distal end of the housing of the drug delivery device.
[0029] Thus, the power supply device may be incorporated into the protective cap of a pen-type drug delivery device. In a further example, the power supply device may include or be implemented as a protective cap of a handheld injection device, such as an injection pen.
[0030] According to a further example, the mechanical mating interface of the body of the power supply device is incorporated or provided at a proximal end of the side wall of the body. In some examples, the mechanical mating interface may be provided at a proximal open end of the receptacle of the body. In this way, a fairly easy and straightforward mutual mechanically removable connection can be provided between the body of the power supply device and the housing or housing component of the drug delivery device.
[0031] According to a further example, the power supply interface of the power supply device includes a first power supply conductor path electrically connecting the power supply interface to the rechargeable energy reservoir. The power supply interface further includes a second power supply conductor path isolated from the first power supply conductor path and electrically connecting the power supply interface to the rechargeable energy reservoir. The first and / or second power supply conductor paths can extend along a longitudinal direction. They can extend from the rechargeable energy reservoir toward a proximal end of the body. When the rechargeable energy reservoir is located at or near a distal end of the body, the first and second power supply conductor paths can extend along substantially the entire longitudinal extent of the body of the power supply device.
[0032] In some examples, the body of the power supply device can have a somewhat tubular or cylindrical shape or structure. Here, the first and second power supply conductor paths can be separated from each other along the circumferential or tangential direction of the side wall of the body. The first and / or second power supply conductor paths can have a somewhat longitudinal linear shape. In this way, the material and cost required to implement the first and / or second power supply conductor paths can be minimized, thereby providing an electrical coupling or connection between, for example, a rechargeable energy reservoir located at or near the distal end of the body and a proximal end of the body that can be mechanically coupled to the power supply device as well as electrically connected.
[0033] According to a further example, at least one of the first and second power conductor paths is disposed on an inner or outer surface of a side wall of the body of the power supply device.
[0034] In some examples, one of the first and second power conductor paths is disposed on an inner surface of the sidewall, and the other of the first and second power conductor paths is provided on an outer surface of the sidewall. In this manner, the first and second power conductor paths are essentially electrically isolated by the sidewall of the body if the material of the sidewall is electrically insulating. This can equally be applied to configurations where the first and second power conductor paths are located at a spatial distance from each other on the same or common side of the sidewall.
[0035] In some examples, at least one of the first and second power conductor paths includes a metallization or metal structure provided on or within the body. Typically, a portion of the body, such as a sidewall or sidewall portion thereof, may be coated, printed, laminated, or glued with the metal or metallization structure. In some examples, at least one of the first and second power conductor paths may be provided on a flexible substrate, such as a flexible foil that is adhesively attached or bonded onto the first elongated device component. In other examples, at least one of the first and second power conductor paths is insert molded into the body, which may be implemented or manufactured as an injection molded plastic component.
[0036] In a further example, the power supply interface of the power supply device includes a first mating power contact electrically connected to the rechargeable energy reservoir and electrically connectable to a complementary shaped first power contact of the drug delivery device. The power supply device, and thus the power supply interface, further includes a second mating power contact electrically connected to the rechargeable energy reservoir and electrically connectable to a complementary shaped second power contact of the drug delivery device. The first and second power contacts can be in direct surface contact with the complementary shaped first and second power contacts of the drug delivery device when the power supply device is mechanically coupled to the drug delivery device, in particular to a housing of the drug delivery device.
[0037] Direct mutual surface contact between the first mating power contact and the first power contact, as well as direct mutual surface contact between the second mating power contact and the second power contact, provides for transmission of electrical energy across the mutually engaged interface of the power supply device and the drug delivery device, i.e., when the power interface is properly engaged with the electrical interface of the drug delivery device.
[0038] According to a further example, the first mating power contact is connected to or incorporated into the proximal end of the first power conductor path. And the second mating power contact is connected to or incorporated into the proximal end of the second power conductor path. In other words, the proximal ends of the first and / or second power conductor paths are provided with or terminated with the first and second mating power contacts, respectively. It is particularly beneficial if at least one of the first mating power contact and the power contact includes a circumferentially widened portion relative to the circumferential extent of the first or second power conductor path in order to provide a good and reliable electrical connection across the power interface engaged with the electrical interface. In this way, a durable and reliable electrical connection between the first and second power contacts, which are complementary in shape to the first mating power contact and the second mating power contact, can be provided even if there is a geometric tolerance in the position or orientation of the body of the power supply device relative to the position or orientation of the housing or housing part of the drug delivery device.
[0039] According to a further example, the first and second mating power contacts are arranged at the proximal end of the body, thus providing a fairly good accessibility for the first and second mating power contacts, thus allowing a fairly easy and straightforward electrical connection with the power contacts of the electrical interface of the drug delivery device.
[0040] According to a further example, the first and second mating power contacts are arranged on or integrated into the mechanical mating interface. In this way, the mechanical mating interface provides a dual function. First, the mechanical mating interface allows mechanical fastening of the body of the power supply device to the drug delivery device, e.g. to its housing. Second, by incorporating the first and / or second mating power contacts into the mechanical mating interface, an electrical connection between the power interface and the electrical interface can be simultaneously provided when the mechanical mating interface engages with the mechanical interface of the drug delivery device.
[0041] In some examples, engagement of the mechanical interface with the mechanical counter interface is accompanied by a feedback signal, e.g., acoustically or tactilely perceptible feedback. Receiving such feedback is a direct indication to the user that not only has a mechanical coupling been established between the power supply device and the housing of the drug delivery device, but also that the power supply interface of the power supply device is electrically connected with the electrical interface of the drug delivery device.
[0042] According to a further example, first and second mating power contacts are disposed on or in a proximal end of a sidewall of the body of the power supply device, which may also be provided on a proximal end face of the sidewall of the body and may longitudinally and / or radially engage or connect with complementarily shaped first and second power contacts provided on or in the drug delivery device when the power supply device is properly assembled or mechanically coupled to the drug delivery device.
[0043] According to a further example, the first and second mating power contacts are arranged circumferentially offset from one another on or in a side wall of the body of the power supply device. If the body of the power supply device is implemented as an injection molded plastic component, the material of the body can provide inherent electrical insulation between the first and second mating power contacts.
[0044] In a further example, the first and second mating power contacts are arranged on or in the side wall with a longitudinal offset from each other. Such a longitudinal offset may be advantageous to avoid cross-connection, i.e., the first mating power contact is connected in contact with the second power contact. Thus, the power contacts as provided on or in the housing of the drug delivery device may also be provided with a longitudinal offset from each other. In this way, an exclusive and clearly defined mutual electrical contact only between the first and first mating power contacts can always be provided, regardless of the rotational position or direction of the body of the power supply device relative to the longitudinal axis as the axis of rotation. Similarly, an exclusive electrical contact can be provided between the second and second mating power contacts.
[0045] In yet another example, the first and second mating power contacts are integrated into the mating fastener. First and second mating fasteners for engaging with complementary shaped first and second fasteners of the mechanical interface of the drug delivery device may also be provided. Here, the first mating power contacts may be integrated into the first mating fastener and the second mating power contacts may be integrated into the second mating fastener. The respective embodiments are provided on the side of the drug delivery device.
[0046] By implementing first and second mating power contacts in at least one mating fastener, and by incorporating the respective first and second power contacts in a complementary shaped fastener on the drug delivery device, electrical contact is automatically provided between the first power contact and the first mating power contact, as well as between the second power contact and the second mating power contact, when the fastener engages with the mating fastener.
[0047] Incorporating electrical contact elements into the mechanical fastening structure of the power supply device is particularly beneficial for establishing and maintaining an electrical connection between the rechargeable energy reservoir and the electronic unit as soon as and while the power supply device is properly attached or mechanically coupled to the drug delivery device.
[0048] According to a further example, the power supply device includes a logic circuit. The logic circuit includes a processor connected to the rechargeable energy reservoir and further connected to at least one of the power supply interface and the charging interface. The processor is operable to control at least one of charging the rechargeable energy reservoir via the charging interface and providing electrical energy to the drug delivery device via the power supply interface. The logic circuit, and thus the processor, may be operable to control depletion of the rechargeable energy reservoir, for example by providing electrical energy to the drug delivery device. Furthermore, it may be operable and configured to control recharging of the rechargeable energy reservoir when the charging interface is electrically connected to an external power source. In this way, a fairly intelligent power management of the rechargeable energy reservoir can be provided.
[0049] According to another example, the power supply device further includes a timer and a signal generator controllable by the processor. The timer and signal generator and the processor may be implemented or integrated on a common printed circuit board. Wherein the processor is operable to start the timer in response to detecting an electrical disconnection or electrical coupling of the power interface from the electronic unit of the drug delivery device. The processor is further operable to stop the timer in response to detecting an electrical reconnection of the power interface to the electronic unit of the drug delivery device.
[0050] Furthermore, the processor is operable to cause the signal generator to generate a time-out warning signal when the count value of the timer exceeds a predetermined maximum count value. Thus, if the power supply device is implemented, for example, as a protective cap for a handheld drug delivery device, the timer can be automatically started by the processor when the processor detects a disconnection of the power supply interface from the electronic unit and thus from the electrical interface of the drug delivery device. Such a disconnection typically occurs when the protective cap is removed from the drug delivery device.
[0051] Thus, when the protective cap is removed from the drug delivery device, the processor of the power supply device starts a timer. When the protective cap is reattached or reassembled to the drug delivery device, the resulting reconnection of the power interface to the electronic unit of the drug delivery device, and thus to the electronic unit of the drug delivery device, can be detected in the same or a similar manner by the processor. The timer can then be stopped and possibly reset by the processor.
[0052] The processor is further operable to couple with the signal generator and generate a time-out warning signal when the count value of the timer exceeds a predetermined maximum count value, which may occur if the protective cap remains detached from the drug delivery device for an unacceptably long time interval. By causing the signal generator to generate the time-out warning signal, the user is then alerted or provided with information that re-coupling of the protective cap to the drug delivery device is due or overdue, respectively.
[0053] The signal generator can be implemented in many different ways. It can be implemented as one of a visual signal generator, an audio signal generator, or a signal generator operable to generate a tactilely perceptible signal. In any case, the signal generator is operable to generate a user-perceptible warning signal to attract the user's attention and prompt the user to return the protective cap, and therefore the power supply device, to the drug delivery device.
[0054] According to another example, the processor is operable to determine a charge level of the rechargeable energy reservoir, where the processor is operable to cause the signal generator to generate an energy depletion warning signal if the charge level falls below a predetermined minimum charge threshold. The minimum charge threshold can be selected such that the remaining electrical energy provided to the rechargeable energy reservoir is sufficient to charge the local battery of the electronic unit at least one more time. However, in some examples, the minimum charge threshold can be set to allow repeated charging of the local battery of the electronic unit of the drug delivery device, thus at least two chargings.
[0055] In any case, when the processor detects that the rechargeable energy reservoir runs out of electrical energy, a respective energy depletion warning signal is generated, thus prompting the user to connect the power supply device to an external power source to charge the rechargeable energy reservoir. In this way, complete depletion of the rechargeable energy reservoir can be avoided.
[0056] Typically, the energy depletion warning signal is at least one of a visual signal, an audio signal, and a tactile signal. The energy depletion warning signal can be distinguished from a time-out warning signal. For example, the energy depletion warning signal may be provided as an audio signal, such as a high-frequency beep. Alternatively, the energy depletion warning signal may be provided in the form of a flashing or continuous light.
[0057] According to another aspect, the present disclosure relates to a drug delivery device configured to set and dispense a dose of a medicament. The drug delivery device includes a housing and an electronic unit disposed on or within the housing. The drug delivery device further includes an electrical interface on or within the housing. The electrical interface is electrically connected to the electronic unit and configured to electrically couple to a power supply interface of a power supply device as described above.
[0058] If the drug delivery device is implemented as a handheld injection device such as a pen injector, the electrical interface may be provided on an outer surface of the housing of the drug delivery device, the electrical interface may be provided at a distal end of a proximal housing member. Alternatively, the electrical interface may be provided at a proximal end of a distal housing member, for example implemented as a cartridge holder. In particular, the electrical interface of the drug delivery device may engage with a power supply interface of a power supply device, and if the power supply device is implemented as a protective cap for the drug delivery device, it is provided at or near the proximal end of the protective cap.
[0059] The electrical interface may thus be provided on an outer surface of the proximal end of the cartridge holder, or on a distal end face, or on an outer surface of the distal end of the body of the housing of the drug delivery device longitudinally adjacent to the cartridge holder.
[0060] According to a further example, the drug delivery device includes a mechanical interface and further includes a power supply device as described above. The power supply device includes a mechanical mating interface that removably fastens to the mechanical interface of the drug delivery device.
[0061] Typically, when the mechanical mating interface of the power supply device engages with the mechanical interface of the drug delivery device, the power supply interface of the power supply device is in electrical contact with the drug delivery device and is thus electrically coupled to the electrical interface of the drug delivery device. Since the electrical interface of the drug delivery device is electrically connected to the electronic unit, the rechargeable energy reservoir of the power supply device can also be appropriately electrically connected to the electronic unit.
[0062] The rechargeable energy reservoir of the power supply device can then be used to recharge or charge the local battery of the electronic unit of the drug delivery device. When the power supply device is removed, the rechargeable energy reservoir of the power supply device is disconnected from the electronic unit of the drug delivery device. The electronic unit of the drug delivery device can then operate standalone based on the electrical energy provided by the local battery of the electronic unit.
[0063] According to another example, the drug delivery device includes a drive unit, e.g., a piston rod movable along a longitudinal direction. The drug delivery device further includes a drug container filled with a drug. The drive unit, e.g., the piston rod, is configured to operatively engage with the drug container to expel or draw a dose of the drug from the drug container.
[0064] A drug delivery device as described above is configured to interact with a power supply device as described above, and to that extent, all configurations, advantages as described above in relation to the power supply device apply equally to the drug delivery device and vice versa.
[0065] Generally, the scope of the present disclosure is defined by the contents of the claims. The injection device is not limited to a particular embodiment or example, but includes any combination of elements of different embodiments or examples. To that extent, the present disclosure encompasses any combination of the claims and any technically feasible combination of the disclosed features in relation to the different examples or embodiments.
[0066] In this context, the term "distal" or "distal end" refers to the end of the injection device that faces towards the injection site of a person or animal, while the term "proximal" or "proximal end" refers to the opposite end of the injection device that is furthest from the injection site of a person or animal.
[0067] The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.
[0068] As described below, drugs or agents may include at least one API or combinations thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
[0069] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.
[0070] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those found in handbooks such as Rote Liste 2014 (e.g., but not limited to, main groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition.
[0071] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residue can be either a codable amino acid residue or another naturally occurring residue or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, e.g., the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.
[0072] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
[0073] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0074] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flathead monster), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C (efpegrenatide). , HM-15211, CM-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, ZP -DI-70, TT-401 (Pegapamodtide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Tirzepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon-Xten.
[0075] Examples of oligonucleotides are, for example, the cholesterol-lowering antisense therapeutic mipomersen sodium (Kynamro®) for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.
[0076] Examples of DPP4 inhibitors are linagliptin, vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.
[0077] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.
[0078] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharma- ceutically acceptable salts. An example of a pharma-ceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.
[0079] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins (CODV) with crossover binding region orientation.
[0080] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment can include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
[0081] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues in the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.
[0082] Exemplary antibodies are anti-PCSK-9 mAb (eg, alirocumab), anti-IL-6 mAb (eg, sarilumab), and anti-IL-4 mAb (eg, dupilumab).
[0083] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.
[0084] Those skilled in the art will understand that modifications (addition and / or removal) of the various components of the APIs, formulations, devices, methods, systems, and embodiments described herein can be made without departing from the full scope and spirit of the invention, which encompasses such modifications and any and all equivalents thereof.
[0085] It will be further apparent to those skilled in the art that various modifications and variations can be made to the present disclosure without departing from the scope of the present disclosure. Furthermore, it should be noted that any reference numbers used in the appended claims should not be construed as limiting the scope of the present disclosure.
[0086] Below, a number of examples of methods for authenticating a user to use a drug delivery device, as well as a number of hardware configurations including a number of implementations of authentication systems, electronic circuits, drug delivery devices, auxiliary devices, and portable electronic devices are described in more detail with reference to the drawings. [Brief description of the drawings]
[0087] [Figure 1] FIG. 1 shows a schematic longitudinal cross-section of an example of a drug delivery device. [Diagram 2] FIG. 2 is an enlarged view of the drive unit of the drug delivery device of FIG. 1. [Diagram 3] FIG. 2 is an enlarged view of a portion of the first and second device components. [Figure 4]FIG. 2 is a close-up view of the electromechanical actuator in an unlocked or released configuration. [Diagram 5] FIG. 2 illustrates an electromechanical actuator during actuation. [Figure 6] 1 is a diagram of voltages on at least one of the conductor paths and / or electrical control paths during a typical usage scenario. [Figure 7] FIG. 13 shows a further example of a drug delivery device having a protective cap provided with an energy reservoir. [Figure 8] FIG. 8 is an enlarged view of the distal end of the protective cap according to FIG. [Figure 9] FIG. 13 shows an example of an interface and a mating interface for fastening a protective cap to a drive unit or to a drug delivery device. [Figure 10] FIG. 1 illustrates an example of an interface having an electrical contact element and a mating contact element. [Figure 11] FIG. 11 shows another example of the interface according to FIG. [Figure 12] FIG. 11 shows a further example of an interface according to FIG. [Figure 13] FIG. 11 illustrates a further example of the interface of FIG. [Figure 14] FIG. 2 shows a further schematic example of a conductive or power path provided across an interface and a mating interface; [Figure 15] FIG. 2 illustrates a cross-section of an example interface coupled to a mating interface. [Figure 16] FIG. 2 shows an example of a mating interface provided at a proximal end of a receptacle unit, configured to be fastened to a first interface of a drive unit. [Figure 17] FIG. 17 shows the interface according to FIG. 16 when engaged. [Figure 18] FIG. 17 shows another example of the interface and the counterpart interface according to FIG. 16. [Figure 19]FIG. 19 shows the interfaces of FIG. 18 when engaged with each other. [Figure 20] FIG. 2 shows cross section AA before and during engagement of the interface. [Figure 21] FIG. 2 shows cross section AA when the interfaces are engaged with each other. [Figure 22] 13A-13C show several examples of mating interfaces of different receptacle units configured to be fastened to a first interface of a drive unit; [Figure 23] FIG. 2 shows a cross section of the first interface of the drive unit. [Figure 24] FIG. 1 is a block diagram of a drug delivery device configured to communicate with an external electronic device. [Diagram 25] FIG. 13 shows another example of a first interface of the drive unit engaging with a mating interface of the receptacle unit. [Figure 26] 1 is a close-up view of the interface before or during assembly or engagement with one another. [Figure 27] FIG. 27 shows the example of FIG. 26 when the interface is engaged or coupled. [Figure 28] FIG. 13 shows another example of a first interface that operates with a mating interface of a receptacle unit before or during assembly with each other. [Figure 29] FIG. 29 shows the interface according to FIG. 28 in the final assembled configuration. [Diagram 30] FIG. 13 shows another example of a drive unit in longitudinal cross section. [Diagram 31] FIG. 31 shows a cross section BB according to FIG. 30. [Diagram 32] FIG. 32 is an enlarged view of the cross section of FIG. 31. [Diagram 33] FIG. 2 is a block diagram of a power supply device. [Diagram 34] 1 is a flow chart of a method of operation of a power supply device. [Diagram 35]5 is a flowchart of a further method of operating a power supply device. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0088] Figures 1, 2, 7 and 30 show in cross-section an exemplary embodiment of a drug delivery device 1. The drug delivery device 1 is a variable dose device, whereby different doses of a drug to be administered can be set or dialed in by the user, respectively. The drug delivery device is a dial extension pen.
[0089] 1 also shows a coordinate system used herein to specify the location of members or elements or configurations. The distal direction D and the proximal direction P run parallel to the longitudinal axis A. The longitudinal axis A is the main axis of elongation of the device 1. The radial direction R is perpendicular to and intersects the longitudinal axis A. The tangential direction, also referred to as the circumferential direction, is perpendicular to the radial direction R and to the longitudinal axis A.
[0090] The drug delivery device 1 includes a drive unit 3 having a setting mechanism and a dispensing mechanism. The setting mechanism is configured to set a drug dose and the dispensing mechanism is configured to dispense a drug dose. The functioning principles of these mechanisms are further explained below.
[0091] The drive unit 3 comprises an inner body 10 and a housing element 11, hereinafter also referred to as outer body 11. The inner body 10 and the outer body 11 are fixedly connected to each other, i.e. they cannot rotate or move axially relative to each other. The outer body 11 forms the outer surface of the drug delivery device 1 that can be touched or grasped by the user.
[0092] The drug delivery device 1 further includes a protective cap 14 and a user interface member 13 in the form of a knob 13. The knob 13 is a dose setting member configured to be operated by a user to set a drug dose and at the same time a dose dispensing member configured to be operated by a user to dispense a drug dose.
[0093] The drug reservoir unit 2, also referred to as container unit 2, comprises a reservoir 16 and a reservoir holder 15 received in a cap 14. The reservoir 16 is filled with a drug or medicament. The reservoir 16 is sealed in a proximal direction P by a stopper 17.
[0094] The reservoir units 2 are operatively coupled or connected, respectively, to a drive unit 3. The drive unit 3 is configured to act on the drug reservoir 16 to effect a dispensing process for dispensing a drug dose. To dispense a drug dose, the stopper 17 is pushed in a distal direction D by a plunger rod 29 of the drive unit 3. When an injection needle 18 is coupled to the drug reservoir, a dose of the drug can be injected into the biological tissue.
[0095] The connection between the drive unit 3 and the reservoir unit 2 is realized by the inner body 10 being connected to the reservoir holder 15 via a connection interface, which may be a snap connection or a screw connection. The connection is preferably reversible. For example, the container unit 2 is axially and non-rotatably fixed to the inner body 10 by this connection.
[0096] The drive unit 3 further includes a number sleeve 26 and a dial sleeve 27 that are fixedly coupled to each other (e.g., cannot rotate or move axially relative to each other). The dial sleeve 27 can include an internal thread that engages with an external thread of the inner body 10. Numbers can be displayed on an outer surface of the number sleeve 26. The numbers are visible to a user through a window 12. The window 12 can include a lens. The window 12 is formed in the outer body 11. The numbers visible in the window 12 indicate to the user the set / dial-set dose. Due to the threaded coupling between the dial sleeve 27 and the inner body 10, the dial sleeve 27 and the number sleeve 26 move on a helical path in a proximal direction relative to the bodies 10, 11 during setting a drug dose and during dispensing a drug dose, as will be further described below.
[0097] The drive unit 3 also includes a drive sleeve. The drive sleeve includes a distal drive sleeve 20, a proximal drive sleeve 21, and a drive sleeve coupler 22 that couples the distal drive sleeve 20 to the proximal drive sleeve 21. To set the drug dose and dispense the drug dose, the distal drive sleeve 20 and the proximal drive sleeve 21 are fixedly coupled to each other via the drive sleeve coupler 22, such that these elements cannot rotate or move axially relative to each other. The distal drive sleeve 20 may include an internal thread that engages with the external thread of the plunger rod 29. The external thread of the distal drive sleeve 20 may engage with the internal thread of a final dose nut 30, the function of which will be further described below.
[0098] Additionally, the drive unit 3 includes a clutch 28 that is fixedly coupled to the knob 13 so that the clutch 28 and knob 13 do not rotate or move axially relative to one another during setting and dispensing of a drug dose. The clutch 28 is coupled to the proximal drive sleeve 20 via a splined engagement that may allow for some axial movement of the clutch 28 relative to the proximal drive sleeve 21, but does not allow for relative rotation between these two elements.
[0099] The distal clicker 23, the proximal clicker 24, and the clutch spring 25 of the drive unit 3 are disposed between the clutch 28 and the drive sleeve coupler 22. The clutch spring 25 is coupled to the drive sleeve coupler 22 and the distal clicker 23. The distal clicker 23 is configured to abut the proximal clicker 24 in the proximal direction P. The proximal clicker 24 is configured to abut the clutch 28 in the proximal direction P. Thus, the clutch spring 25 is configured to bias the distal clicker 23, the proximal clicker 24, and the clutch 28 in the proximal direction P relative to the drive sleeve coupler 22.
[0100] The distal clicker 23 may be permanently splined to the proximal drive sleeve 21 such that relative rotation between these two elements is prevented, but some axial movement between the distal clicker 23 and the proximal drive sleeve 21 may be permitted. The proximal clicker 24 may be permanently splined to the inner body 10 such that relative rotation between these two elements is prevented, but some relative axial movement may be permitted.
[0101] The distal surface of the clutch 28 and the proximal surface of the proximal clicker 24 may both be toothed such that the two surfaces can engage with each other. Furthermore, the distal surface of the proximal clicker 24 and the proximal surface of the distal clicker 23 may both be toothed such that the two toothed surfaces can engage with each other. The proximal surface of the clutch 28 may be toothed, for example with dog teeth, and may be arranged to engage with a toothed, for example with dog teeth, distal surface of the dial sleeve 27.
[0102] FIG. 1 shows the drug delivery device 1 when no dose is set (0 units / 0 units position). Setting of the dose can be possible in discrete units of 1, for example 0-80 units. To set the desired drug dose, the user must rotate the knob 13. This is done without pushing the knob 13 in the distal direction D. Unless the knob 13 is pushed in the distal direction D, the clutch spring 25 biases the clutch 28 in the proximal direction P, or at least prevents the clutch 28 from moving naturally in the distal direction D, so that a dog-tooth engagement between the clutch 28 and the dial sleeve 27 is established. The dog-tooth engagement between the clutch 28 and the dial sleeve 27 results in the two elements being locked together, so that when the knob 13 rotates, the dial sleeve 27 and the number sleeve 26 also rotate. Because the dial sleeve 27 is threadably engaged with the inner body 10, rotation of the knob 13 results in the knob 13, clutch 28, dial sleeve 27, and number sleeve 26 moving on a helical path in the proximal direction P relative to the bodies 10, 11. This causes the number on the number sleeve 26 visible through the window 12 to increase.
[0103] The proximal drive sleeve 21 is splined to the clutch 28 so that the proximal drive sleeve 21 , and with it the distal drive sleeve 20 and drive sleeve coupler 22 , move on a helical path in the proximal direction P relative to the inner body 10 .
[0104] The plunger rod 29 includes two overlapping external threads of opposite winding sense that are in threaded engagement with the internal threads of the distal drive sleeve 20. These threads are selected such that the plunger rod 29 does not rotate or move axially during the helical movement of the distal drive sleeve 20 in the proximal direction P.
[0105] The final dose nut 30 may be splined to the inner body 10 and therefore cannot rotate relative to the inner body 10. As the final dose nut 30 is threadedly engaged with the distal drive sleeve 20, the final dose nut 30 is forced to move in the proximal direction P during setting of the drug dose. When the maximum dose is set (e.g., a maximum dose of 80 units is set, whether set in a single or multiple drug setting process), the final dose nut 30 establishes a rotation lock interface with the distal drive sleeve 20, which prevents the final dose nut 30 from rotating further relative to the distal drive sleeve 20. As a result, the distal drive sleeve 20 cannot rotate further and no further drug doses can be set. The drug delivery device 1 must then be reset to its initial state.
[0106] During setting of the drug dose, the mutually facing toothed surfaces of the distal clicker 23 and the proximal clicker 24 ride over each other in a ratcheting manner, thereby producing a clicking sound that indicates to the user that the drug dose has been set. For this purpose, the teeth of the two surfaces are preferably formed as shallow triangles, which allow relative rotation between the clickers 23 and 24, causing the clutch spring 25 to undergo slight repeated compression and expansion.
[0107] After setting the desired dose, the user can now push the knob 13 in the distal direction D to dispense the set drug dose. This transfers the distally directed force on the knob 13 from the knob 13 through the clutch 28 to the proximal clicker 24 and from the proximal clicker 24 to the distal clicker 23, compressing the clutch spring 25. Now, the two clickers 23 and 24 are pressed against each other and their toothed surfaces engage. Now, relative rotation between the two clickers 23, 24 is prevented. Since the proximal clicker 24 is splined to the inner body 10 and the distal clicker 23 is splined to the proximal drive sleeve 21, the proximal drive sleeve 21 cannot rotate any further relative to the inner body 10. However, since the proximal drive sleeve 21 is also splined to the clutch 28, the clutch 28 and the knob 13 cannot rotate any further relative to the inner body 10.
[0108] A distally directed force applied to the knob 13 results in the clutch 28 together with the knob 13 moving slightly in the distal direction D relative to the dial sleeve 27, as already mentioned, thereby compressing the clutch spring 25. This releases the dog tooth engagement between the dial sleeve 27 and the clutch 28, so that the dial sleeve 27 is no longer locked against further rotation relative to the clutch 28. Thus, when the knob 13 is pushed in the distal direction D, the dial sleeve 27 together with the number sleeve 26 can still rotate relative to the inner body 10. Now, when the knob 13 is moved in the distal direction D, the stop on the dial sleeve 27 forces the dial sleeve 27 to also move in the distal direction D. Due to the threaded engagement of the dial sleeve 27 with the inner body 10, the dial sleeve 27 moves on a helical path together with the number sleeve 26 in the distal direction D. This causes the number of the number sleeve 26 visible in the window 12 to decrease.
[0109] At the same time, the clutch 28, the clickers 23, 24 and the drive sleeves 20, 21, 22 are forced to move (without rotating) in the distal direction D. The threaded engagement between the plunger rod 29 and the distal drive sleeve 20 forces the plunger rod 29 to rotate. Further threaded engagement between the plunger rod 29 and the internal thread of the inner body 10 can then force the plunger rod 29 to move in the distal direction D to push the stopper 17 inside the cartridge 16 in the distal direction D to dispense the set drug dose. Since the distal drive sleeve 20 does not rotate during dispensing, the final dose nut 30 moves in the distal direction D together with the distal drive sleeve 20 without changing its position relative to the distal drive sleeve 20.
[0110] After dispensing the set drug dose, when the knob 13 has been fully returned to its initial position, a new drug dose can be set by rotating the knob 13 again on a helical path in the proximal direction P. During this time, the plunger rod 29 does not change its position. Only when dispensing a dose is the plunger rod 29 moved in the distal direction D.
[0111] As described with respect to Figure 1, one user interface member in the form of knob 13 is used for both setting the drug dose and dispensing the drug dose, however, it is also possible to use separate user interface members for setting and dispensing the drug dose.
[0112] Further examples of drive units 3 implemented with injection devices 1 can be found in WO2014 / 033195A1 or WO2014 / 033197A1, which are incorporated herein by reference in their entirety.
[0113] Figures 2 to 33 show the drug delivery device 1 of Figure 1, but in different views and in more detail than in Figure 1. Figure 2 shows only the proximal part of the drug delivery device 1 to better explain some of the details.
[0114] The drug delivery device 1 is provided as a pen-type injection device that is entirely mechanically implemented. Thus, all the force required to inject the medicament is provided by the user of the device. The drug delivery device 1 can be implemented as a disposable device. Such a device is intended to be discarded when the medicament provided in the medicament container 16 is used up. In another example, the drug delivery device is implemented as a reusable device. Here, the drive unit 3 forming or constituting the proximal part of the drug delivery device is provided with a coupling interface 8 that provides a mechanically releasable coupling with the container unit 2. The drug delivery device can further include a further coupling interface 7, whereby the protective cap 14 is removably fixable to at least one of the housing 6, e.g. the drive unit housing 9 and the cartridge holder 15. Generally, the housing 6 of the drug delivery device includes a proximally located drive unit housing 9 that is coupled or coupleable with the container unit 2. The container unit 2 includes a cartridge holder 15 that serves as a distal housing component of the drug delivery device 1. The cartridge holder 15 should typically be covered by the protective cap 14 when the drug delivery device is not in use.
[0115] As shown in more detail in FIG. 2, the drive unit 3 is provided with an electronic unit 70. The electronic unit 70 is located in a hollow space covered by the dose button 13. The electronic unit 70 is provided near or at the proximal end 5 of the drive unit 3. At or near the opposite distal end, the drive unit 3 includes a first interface 110. The first interface 110 is provided with a first electrical contact element 111 and a second electrical contact element 112. The first and second electrical contact elements 111, 112 may be provided in a receptacle at the distal end 4 of the drive unit 3. The receptacle may be sized and configured to receive a complementary shaped insertion section of the cartridge holder 15.
[0116] The first electrical contact element 111 is connected to a first conductor path 141 located on or within the first elongated device component 40. In the example shown here, the first elongated device component 40 is provided by the inner body 10 of the drive unit 3. Alternatively, it may be provided by any other elongated component of the drive unit 3, as described above.
[0117] The first device component 40 has a somewhat tubular and elongated shape. As shown, a first conductor path 141 extends along the inner surface 43 of the sidewall 41 of the first device component 40. Similarly, a second conductor path 151 is provided. The second conductor path 151 is also provided on the inner surface 43 of the sidewall 41 of the first elongated device component 40.
[0118] The first and second electrical contact elements 111, 112 are provided on a distally-facing longitudinal end surface 44 of the first housing component, where the longitudinal or distal ends 142, 152 of the first and second conductor paths 141, 151 are in permanent electrical contact with the first and second electrical contact elements 111, 112, respectively. At the opposite longitudinal end, the first elongated device component 40 includes a proximally-facing longitudinal end surface 45.
[0119] Proximal ends 143, 153 of the first and second conductor paths 141, 151 terminate at the respective longitudinal end faces 45. As shown in FIG. 2, the proximal ends 143, 153 extend radially outward at the longitudinal end faces 45 of the first device component 40.
[0120] The drive unit 3 further comprises at least a second device component 60, here implemented as a dial sleeve 27 and / or a number sleeve 26. The second device component 60 is also tubular in shape. Alternatively and generally, the second device component may be represented by any component of the drive unit 3 as described above, which is movable relative to the first device component 40.
[0121] The first device component 40 is located inside the second device component 60. The tubular sidewall 61 of the second device component 60 surrounds the outer surface 42 of the first device component 14. Furthermore, the first device component 40 and the second device component 60 are threadedly engaged. Thus, the outer surface 42 of the first device component 40 is provided with a threaded section 46 which threadably engages with a correspondingly shaped threaded section 66 on the inner surface 63 of the second device component 60. In this way, the second device component 60 is movable relative to the first device component 40 along a helical path.
[0122] On the inside of the sidewall 61 of the second device component 60, e.g., towards a proximal end of the second device component 60 formed, e.g., by the dial sleeve 27, there are provided a first conductor path extension 145 and a second conductor path extension 155. The first and second conductor path extensions 145, 155 are provided on a side surface 63 of the sidewall 61 of the second device component 60.
[0123] The first conductor path extension 145 and the second conductor path extension 155 have a helical wound structure having multiple turns. The helical wound structure of the first conductor path extension 145 and the helical wound structure of the second conductor path extension 155 may be nested or spirally disposed on the inner surface 63 of the sidewall 61 of the second device component 60. Towards the proximal end 65, the first and second conductor path extensions 145, 155 are fairly straight and are further electrically connected to the electronic unit 70.
[0124] As shown in Figure 2, the proximal end 143 of the first conductor path 141 is in sliding contact with a first conductor path extension 145. Details of this sliding contact 144 will be further described with respect to Figures 31 and 32. Similarly, the proximal end 153 of the second conductor path 153 is provided with a sliding contact 154 in face contact with a second conductor path extension 155.
[0125] The helical structure of the first and second conductor path extensions 145, 155 has the same lead as the threaded engagement between the first device component 40 and the second device component 60. In this way, for example, when the second device component 60 undergoes a helical motion relative to the first device component 40, electrical contact between the first conductor path 141 and the first conductor path extension 145 is maintained. The same applies to the second conductor path 151 and the second conductor path extension 155.
[0126] 2-5 further show a first electrical control path 181 and a second electrical control path 191. The first and second electrical control paths 181, 191 extend from the electronic unit 70 towards the electromechanical actuator 50 located at a longitudinal distance from the proximal end 5 of the drug delivery device 1. The first electrical control path 181 includes a proximal end 183 that is permanently connected to the electronic unit 70. Similarly, the second electrical control path 191 includes a proximal end 193 that is permanently connected to the electronic control unit 70. The electronic control unit 70 is disposed or attached to the proximal end of the second device component 60. The electronic control unit 70 may be located at a proximal end face of the second device component 60.
[0127] The first electrical control pathway 181 and the second electrical control pathway 191 are located on or within the second device component 60. They extend longitudinally along or within the sidewall 61 of the second device component 60. As shown in Figures 2-5, the electromechanical actuator 50 is provided on or within the inner body 10. The electromechanical actuator 50 may be integrally formed with the first device component 40. The electromechanical actuator 50 may include a bending arm 55 extending in a longitudinal direction A. The electromechanical actuator 50 includes a free end towards or at its proximal end. The proximal or free end of the bending arm 55 is provided with a radially inwardly extending protrusion 53 that engages with a complementary shaped recess 54 provided in the second device component 60.
[0128] The electromechanical actuator 50 includes a first magnet 51, for example, provided on or within the outer body 11 as shown in FIGS. 4 and 5. The electromechanical actuator 50 further includes a second magnet 52 longitudinally aligned with the magnet 51. The second magnet 52 can be implemented as an electromagnet. The second magnet 52 is electrically connected to a first control path extension 185 and a second control path extension 195. By providing a current through the first and second control path extensions 185, 195, the second magnet 52 generates a magnetic field, for example, which interacts with the static magnetic field of the first magnet 51, resulting in an attraction or repulsion between the first magnet 51 and the second magnet 52.
[0129] The bending arm 55 is elastically deformable in the radial direction. By suitably driving the electromagnet 52 with a drive current, a radially directed movement of the bending arm 55, and thus of the protrusion 53, can be induced. Thus, by applying a current to the electromagnet 52, a mechanical engagement between the protrusion 53 and one of a number of recesses 54 provided on the outer surface of the second device component 60 can be established or nullified.
[0130] In Figure 4, an unlocked configuration is illustrated, in which the bent arm 55, and therefore its protrusion 53, is not engaged with the recess 54. In Figure 5, activation or actuation of the electromagnet 52 results in a radially inwardly directed movement of the protrusion 53, thereby engaging the protrusion 53 with the recess 54. Because the bent arm 55 is fixedly attached to the inner body 10, the second device component 60, and in particular the number sleeve 26, is locked against rotation. Thus, in the locked configuration as shown in Figure 5, at least one of setting a dose and injecting a dose is locked.
[0131] In another example, when the electromechanical actuator 50 is deactivated or in an initial state, the locking mechanism 56 is activated, such that the protrusions 53 are engaged with the recesses 54. Therefore, by default, the interlock and therefore the locking mechanism 56 is activated. Activation of the electromechanical actuator 50, for example by applying a current to the electromagnet 52, unlocks the locking mechanism 56.
[0132] Control signals for activating or deactivating the electromagnet 52 are generated and provided by the electronic unit 70. The control signals are transmitted via first and second electrical control paths 181, 191 and a mutual electrical contact arrangement between the first electrical control path 181 and the first control path extension 185, as well as via the second electrical control path 191 and the second control path extension 195, as shown in more detail in FIG.
[0133] The first and second control path extensions 185, 195 each include a proximal end connected to an electromagnet 52 provided on the bending arm 55. The first and second control path extensions 185, 195 may be provided on or within the bending arm 55. They are electrically insulated from one another. As shown in FIG. 2, toward the distal end of the bending arm 55, the first and second control path extensions 185, 195 extend toward and onto the outer surface 42 of the sidewall 41 of the first elongate device component 40, which may be integrally formed with the bending arm 55.
[0134] As shown in FIG. 3, the first and second control path extensions 185, 195 are provided in a helical configuration on the exterior surface 42. The first and second control paths 181, 191 extend onto or through the second device component 60 which is in threaded engagement with the first device component 40. As shown in FIG. 3, the distal end 182 of the first electrical control path 181 is connected to the first control path extension 185 via a sliding contact 184. Similarly, the distal end 192 of the second electrical control path 191 is connected to the second control path extension 195 at a further sliding contact 194.
[0135] The lead of the helical structure of the first and second control pathway extensions 185, 195 is substantially equal to the lead of the threaded section 66 of the second device component 60 which is in threaded engagement with the complementary shaped threaded section 46 of the first device component 40. In this manner, electrical contact between the first and second electrical control pathways 181, 191 and the respective first and second control pathway extensions 185, 195 can be maintained as the second device component 60 undergoes helical motion relative to the first device component 40, e.g., during dose setting and / or dispensing.
[0136] As shown in Figures 7 and 8, there is further provided a power supply device 300 including a body 240, which in this example coincides with the body of the protective cap 14. Thus, the power supply device 300 is formed or constituted by the protective cap 14. The body 240 includes a somewhat tubular side wall 241. The side wall 241 forms or constitutes a receptacle 244 that is open towards the proximal direction. The receptacle 244 is sized to receive the cartridge holder 15 of the drug delivery device 1.
[0137] The power supply device 300 includes a power supply interface 310 configured to electrically couple or connect with the electrical interface 130 of the drug delivery device 1. The power supply device 300 further includes a charging interface 320. Both the charging interface 320 and the power supply interface 310 are electrically connected to a rechargeable energy reservoir 250 of the power supply device 300. The energy reservoir 250 may also be implemented as a secondary battery or a rechargeable battery.
[0138] The rechargeable energy reservoir 250 can be connected or coupled to the external power source 400 by a charging interface 320, for example, provided at the distal end 242 of the body 240. The distal end 242 of the body 240 includes a power connector 252 electrically connected to the rechargeable energy reservoir 250. The power connector 252 can include a socket 242 configured to engage or receive a mating plug 422 of the external power source 400.
[0139] 8, the mating plug 422 can be flexibly and / or movably connected to the external power source by a cable 421. Alternatively, the electrical connection or coupling between the external power source 400 and the charging interface 320 may provide wireless charging, where the external power source 400 can include an inductive coupler 424. The power connector 252 can include a complementary shaped mating inductive coupler 324 operable to inductively couple with the inductive coupler 424 when in proximity to the external power source 400.
[0140] As further shown in Figures 7 and 8, the drug delivery device 1, and thus the drive unit 3, is provided with a first power supply conductor path 161 and a second power supply conductor path 171. The drive unit 3 includes a second interface 120 implemented as a mechanical interface, for example provided at or near the distal end 4 of the drive unit housing 9. The mechanical interface 120 is operable and configured to removably couple with a mechanical counter interface 220 provided at or near the proximal end 243 of the body 240 of the protective cap 14. Interaction and engagement of the mechanical interface 120 with the mechanical counter interface 220 allows the protective cap 14 to be removably coupled to the housing 6 of the drug delivery device 1.
[0141] In this example, the mechanical interface 120 also includes an electrical interface 130 configured and operable to electrically engage a power interface 310 of the power delivery device 300. The power interface 310 is integrated into the mechanical counterpart interface 220 of the body 240. In this manner, by establishing a mechanical coupling between the mechanical interface 120 and the mechanical counterpart interface 220, an electrical connection between the power interface 310 and the electrical interface 130 is automatically established.
[0142] The electrical interface 130 includes a first power contact 121 electrically connected to a first power conductor path 161. The electrical interface 130 further includes a second power contact 122 electrically connected to a second power conductor path 171.
[0143] The first and second power contacts 121, 122 are configured to make electrical contact with a complementarily shaped power interface 310 of the power delivery device 300. The power interface 310 includes first and second mating power contacts 221, 222 and is provided at a proximal end of the protective cap 14.
[0144] In practice, the mating power contacts 221, 222 are electrically connected to an energy reservoir 250 provided in or on the protective cap 14. The energy reservoir 250, for example implemented as a secondary battery, is electrically connected to the first mating power contact 221 via a first power path 261. The second mating power contact 222 is connected to the energy reservoir 250 by a second power path 271. As shown in FIG. 7, the distal end 262 of the first power path 261 is connected to the electrical energy reservoir 250. The proximal end 263 is electrically connected to the first mating power contact 221. Similarly, the distal end 272 of the second power path 271 is electrically connected to the electrical energy reservoir 250.
[0145] The first and second power pathways 261, 271 are disposed on an inner surface 245 of the sidewall 241 of the hollow receptacle 244 of the body 240. In another example (not shown), the first and second power pathways 261, 271 may also be disposed on an outer surface 246 of the sidewall 241 of the body 240.
[0146] The opposite proximal end 273 of the power path 271 is electrically connected to the second mating power contact 222. As shown in FIG. 7, the first and second power paths 261, 271 are electrically insulated from each other. They are provided on the inner surface of the side wall 241 of the cap body 240 of the protective cap 14. The electrical energy reservoir 250 is located at or near the distal end 242 of the cap body 240. The mating power contacts 221, 222 are located at or near the proximal end 243 of the protective cap 14.
[0147] When the protective cap 14, and thus the power supply device 300, is properly assembled to the drug delivery device 1, the first power contact 121 is electrically connected to the first mating power contact 221. Similarly, the second power contact 122 is electrically connected to the second mating power contact 222. In this way, the first and second power conductor paths 161, 171 are electrically connected to the electronic unit 70, so that electrical energy can be provided to the electronic unit 70. In particular, the battery 73 of the electronic unit 70 can be charged by the electrical energy provided by the electrical energy reservoir 250 of the protective cap 14.
[0148] As further shown in Figures 7 and 30, the first and second power conductor paths 161, 171 are indirectly connected to the electronic unit 70 via first and second power conductor path extensions 165, 175. The first and second power conductor paths 161, 171 are disposed on the outer surface of the sidewall of the outer body 11. Similarly, they may be provided on the inner surface of the outer body 11. Alternatively, they may be provided on the outer surface of the inner body 10 and thus on the outer surface of the first device component 40.
[0149] 30, the power conductor path extensions 165, 175 are directly electrically connected to the electronic unit 70. They are spirally disposed on the outer surface 62 of the second housing component 60. The proximal ends 163, 173 of the first and second power conductor paths 161, 171 terminate at the proximal end of the first device component 40, here implemented as the outer body 11.
[0150] A proximal end 163 of the first power conductor path 161 is electrically connected to a first power conductor path extension 165 via a sliding contact 164. Similarly, a proximal end 173 of the second power conductor path 171 is electrically connected to a second power conductor path extension 175 by another sliding contact 174. In this way, a permanent electrical contact can be provided between the first and second power contacts 121, 122 provided at or near the distal end 4 of the drive unit 3 and the electronic unit 70 provided at or near the proximal end 5 of the drive unit 3, even when the second device component 60 undergoes a spiral motion relative to the first device component 40.
[0151] As further shown in Fig. 8, the protective cap 14 is provided with a printed circuit board (PCB) 251 and a logic circuit 255. The PCB 251 is further provided with a power connector 252. The power connector 252 provides an electrical connection to an external power source to recharge the energy reservoir 250. Typically, the energy reservoir 250 is implemented as a rechargeable battery. The energy reservoir 250 typically has a storage capacity substantially larger than the storage capacity of each of the batteries 73 of the electronic unit 70.
[0152] Furthermore, a signal generator 254 connected to the logic circuit 255 may be provided on or in the protective cap. The signal generator 254 is operable to generate and / or transmit at least one of a visual signal, an audible signal, or a tactile signal. In this way, the logic circuit 255 may be configured to autonomously generate a warning signal, for example, in a situation where the deactivation of the electrical contact with the electronic unit 70 exceeds a predetermined time interval. In a situation where the protective cap 14 is not reassembled to the drive unit 3 or to the drug delivery device 1 after use, the warning generated by the signal generator 254 may remind the device user to return the protective cap 14 to the drug delivery device 1.
[0153] Furthermore, the electronic circuitry 255 may be operable to monitor and / or detect the charge level of the energy reservoir 250. If the logic circuitry 255 detects that the charge level is below a predetermined minimum threshold, the logic circuitry 255 may be configured to cause a respective alert to be generated via the signal generator 254. In this way, a user of the device may be prompted to connect the protective cap 14, and thus the entire drug delivery device 1, to an external power source in order to recharge the energy reservoir 250.
[0154] 30, the first and second conductor path 141, 151 are located and disposed inside the outer body 11. The first and second conductor path extensions 145, 155 are provided and disposed on the outer surface 62 of the side wall 61 of the second housing component 60. Here, the first and second conductor path extensions 145, 155, together with the first and second power conductor path extensions 165, 175, are nested or spirally disposed, thus in an alternating arrangement, on the outer surface 62 of the side wall 61 of the second housing component 60.
[0155] Again, the leads of the helical structure of the various conductor path extensions 145 , 155 , 165 , 175 are substantially identical to the leads of the threaded engagement between the first device component 40 and the second device component 60 .
[0156] The cross-sections according to Figs. 31 and 32 show details of one embodiment of the sliding contacts 144, 154, 164, 174. Each sliding contact 144, 154, 164, 174 includes at least one mechanically biased contact conductor 146, 156, 166, 176. In the example of the sliding contact 144, the contact conductor 146 is connected to one of the first conductor path 141 and the first conductor path extension 145. The mechanically biased contact conductor 146 can be implemented as a flexible or elastically deformable conductive tongue that is essentially biased in the radial direction to maintain electrical contact between the first conductor path 141 provided in the interior of the first device component 40 and the first conductor path extension 145 provided on the outer surface of the second device component 60.
[0157] In another example, the mechanically biased contact conductor 146 may include a biasing spring, ie, a conductive pin that is movable against or under the action of a contact spring.
[0158] Additional contact conductors 156, 166, 176 may be implemented in a similar manner.
[0159] 9-15 show the mechanical interaction between the second interface 120 and the mating interface 220 of the protective cap 14. Here, the mechanical engagement between the interfaces 120, 220 is implemented as a snap feature or snap-type connection. The second interface 120 includes a fastener 124 implemented as a snap element 125. The snap element 125 includes a radial protrusion 126 at its distal end followed by a recess 127 in the longitudinal direction. The mating interface 220 thus includes a complementary shaped mating fastener 224 or a respective mating fastener structure. The mating fastener 224 includes a complementary shaped mating snap element 225. The mating snap element 225 includes a protrusion 227, e.g. a radial protrusion, followed by a recess 226 at its proximal end. When properly assembled, the protrusion 227 engages in the recess 127 and the protrusion 126 engages in the recess 226.
[0160] As further shown in Figures 10 to 13, the power contacts 121 may be provided inside one of the recesses 127 and the protrusions 126. Thus, the complementary shaped mating power contacts 221 are provided in one of the protrusions 227 and the recesses 226. In the example of Figures 10 and 12, the power contacts 121 terminate in the recesses 127. The complementary shaped mating power contacts 221 terminate on the respective surfaces of the protrusions 227.
[0161] 11 and 13, power contact 121 terminates on protrusion 126. A complementary shaped mating power contact 221 is provided across recess 226 and may even extend towards and into protrusion 227.
[0162] In the further view of FIG. 14, each interface 120, 220 is provided with two power contacts 121, 122 and respective first and second counter power contacts 221, 222. Here, the first power contact 121 is located in a recess 127. The second power contact 122 is provided at a longitudinal distance from the first power contact 121. Thus, the second power contact 122 is provided on or in the protrusion 126. Thus, the first counter power contact 221 is provided on the protrusion 227 and the second counter power contact 222 is provided on or in the recess 226. When properly connected and a snap-fit connection is established between the second interface 120 and the counter interface 220, the first power contact 121 is exclusively connected with the first counter power contact 221. Similarly, the second power contact 122 is in electrical contact with the second counter power contact 222.
[0163] The cross section according to Fig. 15 shows that the first and second power contacts 121, 122 have a somewhat circular or at least semicircular shape and extend along the circumference of the drive unit housing 9 or cartridge holder 15. The complementary shaped mating power contacts 221, 222 may vary with respect to their circumferential position, as indicated by the dashed lines of the first and second mating power contacts 221', 222'. This allows the protective cap 14 to be rotated relative to the inner or outer body 10, 11 within a predefined range, as defined for example by the fastener 124 and the mutually corresponding mating fastener 224, thereby maintaining electrical contact.
[0164] As shown, the circumferential extent of the first and second electrical mating power contacts 221, 222 is slightly less than the circumferential gap between the first power contact 121 and the second power contact 122. In this manner, a short circuit between the first power contact 121 and the second power contact 122 by any of the first or second mating power contacts 221, 222 can be effectively prevented.
[0165] In the diagrams of Figs. 16-21, an example of a mechanical connection between the drive unit 3 and the receptacle unit 2 is exemplarily shown. The drive unit 3 includes a first interface 110 that is complementary shaped and configured to engage with a respective mating interface 210 provided at the proximal end of the receptacle unit 2. As shown, the first interface 110 includes a receptacle that is configured and shaped to receive an insertion section provided at the proximal end of the receptacle unit 2. The distal end of the drive unit 3, in particular the distal end of the drive unit housing 9, includes a fastener 114 that is configured to engage with a complementary shaped mating fastener 214 of the mating interface 210. As shown in Figs. 16-19, the interconnection between the fastener 114 and the mating fastener 214 can include or form a bayonet joint. Other types of connections, such as a snap-fit connection or a threaded connection, are equally available or conceivable.
[0166] 16, the mating interface 210 of the receptacle unit 2 is provided with a first mating contact element 211 and a second mating contact element 212. The first and second mating contact elements 211, 212 include somewhat chamfered or angled proximal end faces. The first and second contacts 111, 112 provided on or in the first interface 110 can be selectively electrically connected by an electrical connector 115 movably disposed in or on the first interface 110.
[0167] A carrier 119 may be provided which is longitudinally displaceable against or under the action of the contact spring 116. In the view of FIG. 16, the electrical connector 115 is provided on the carrier 119. The electrical connector 115 is not in contact with the first and second electrical contact elements 111, 112. When the receptacle unit 2 is coupled to the drive unit 3, the counter contact elements 211, 212 engage with the carrier 119 and urge the carrier 119 in the proximal direction against the action of the contact spring 116. When the final assembled configuration is reached in which the counter fastener 214 is fully engaged with the fastener 114, the carrier 119 and the contact conductor 115 provided on the carrier 119 have moved to the contact position of the first electrical contact element 111 and the second electrical contact element 112. In this way, the electrical contact between the first electrical contact element 111 and the second electrical contact element 112 is closed. Therefore, a closed conductor loop is provided between the first conductor path 141 and the second conductor path 161 .
[0168] 18 and 19, the electrical connector 115 includes a first electrical contact element 117 and a second electrical contact element 118 located or disposed on a movable carrier 119. Here, the first and second contact elements 117, 118 of the electrical connector 115 are electrically insulated from each other. They can individually make electrical contact with the first and second electrical contacts 111, 112 of the first interface 110.
[0169] Thus, the mutual electrical contact between the first electrical contact 111 and the second electrical contact 112 is provided by mechanical engagement with the first and second counter contact elements 211, 212, on which separate contact conductors 215 are provided. Here, the surfaces of the first and second counter contact elements 211, 212 can be provided with electrically conductive structures or materials. Furthermore, the first and second counter contact elements 211, 212 are electrically connected via the contact conductors 215. In the final assembly configuration, which is not yet reached in FIG. 19, the first electrical contact element 111 is electrically connected to the further contact element 117. The further contact element 117 is electrically connected to the counter contact element 211. The counter contact element 211 is permanently electrically connected to the counter contact element 212. The mating contact element 212 is also in electrical contact with a further contact element 118 of the electrical connector 115 , which contact element 118 is further electrically connected with the second electrical contact element 112 .
[0170] 20 shows cross section AA, which represents the configuration before the final assembled position is reached and before the mating fastener 214 reaches its end position in the groove of fastener 114. Here, the mating contact elements 211, 212 are circumferentially offset from the contact elements 117, 118. When the final assembled position is reached, the respective contact configuration is obtained.
[0171] In the example of Fig. 25-29, another way of establishing electrical contact between the first interface 110 and the mating interface 120 is shown diagrammatically. Here, the first or second contact 111, 112 is provided with a conductive contact element 117, which is movably arranged or movably connected to the distal end 152 of the second conductor path 151. The proximal end of the cartridge holder 15 can be provided with a respective mating contact element 212. The mating contact element 212 can be provided as a conductive structure on the proximal end face of the side wall of the cartridge holder 15. It can comprise an annular closed conductive ring structure on the proximal end or end face of the cartridge holder 15. In the configuration as shown in Fig. 26, the final assembly position has not yet been reached. Here, the mating contact element 212 and the contact element 117 are not engaged.
[0172] 27, the contact element 117 is in surface contact with the mating contact element 212. Furthermore, the contact element 117 is mechanically biased by a contact spring 116. The contact spring 116 may be made of a conductive material and may provide for the transmission of electrical signals between the contact element 117 and the conductor path 151, respectively.
[0173] In a further example as shown in Fig. 28 and Fig. 29, the contact element 117 of the second electrical contact element 112 is implemented as a soft or elastically deformable convex edge which is deformable or pivotable towards the proximal direction when engaging with a counter contact element 212 provided at the proximal end of the receptacle unit 2. The counter contact element 212 can have an annular structure at the proximal end of the side wall of the cartridge holder 15. In the proximal contact position, the counter contact element 212 is electrically connected to both contact elements 111, 112. In this way, the presence of the cartridge holder 15 and the correct attachment of the cartridge holder 15 to the drive unit 2 can be detected electronically.
[0174] FIG. 22 illustrates a series of differently configured mating interfaces 210, 210', 210'' for a series of different types of container units 2, 2', 2'', typically with different drug containers 16 and / or different medicaments. The mating interfaces 210, 210', 201'' are electrically coded by the position or orientation of the mating contact elements 211, 212 as shown in FIG. 22. Furthermore, the mating interfaces 210, 210', 210'' are provided with identical mating fasteners 214 configured to mechanically engage with a complementary shaped fastener 114, similar to the first interface 110 of the drive unit 3. In this figure, two fasteners 114 are provided with a certain angular offset.
[0175] The mating fasteners 214 of the various container units 2, 2', 2'' are provided with respective angular offsets. In this way, the mating interfaces 210, 210', 210'' can be fastened in only one distinct orientation with respect to the longitudinal axis as the axis of rotation A.
[0176] 23, the first interface 110 includes not only the first electrical contact element 111 and the second electrical contact element 112, but also a third electrical contact element 131 and a fourth electrical contact element 133. The third contact element 131 is connected to a third longitudinally extending conductor path 132. The fourth contact element 133 is connected to a respective conductor path 134. These auxiliary conductor paths 133, 134 can be connected to the electronic unit 70 in the same or similar conductive manner as the first and second conductor paths 141, 151.
[0177] In a multiple receptacle unit and mating interface 210, 210', 210'', as shown in Fig. 22, there is always provided a common mating contact element 212 which is located at the same position relative to the mating fastener 214. In a multiple mating interface 210, 210', 210'', the position of the further mating contact elements 211, 211', 211'' varies in the circumferential direction relative to the mating contact element 212 and / or relative to the mating fastener 214.
[0178] Only one of the contact elements 131, 111, 133 can be electrically connected to the mating contact element 211, 211', 211''. For example, in the mating interface 210, the mating contact element 211 is electrically connected to the mating contact element 212. In the mating interface 210', the mating contact element 212 is electrically connected to the mating contact element 211', and in the mating interface 210'' the mating contact element 212 is electrically connected to the mating contact element 211''.
[0179] Here, when the mating interface 210 is coupled to the first interface 110, the electrical contact element 112 is in electrical contact with the mating contact element 212. Furthermore, the contact element 111 is in electrical contact with the mating contact element 211. Thus, the electronic unit 70 can sense or detect the electrical contact between the first electrical contact element 111 and the second electrical contact element 112, and thus can identify the presence and / or correct assembly of the receptacle unit 2 and the drive unit 3.
[0180] When the further mating interface 210' engages with the first interface 110, the mating contact element 211' is in electrical contact with the third electrical contact element 131. The mating contact element 212 is in electrical contact with the second contact element 112. Thus, the electronic unit 70 can detect the electrical connection between the second contact element 112 and the third contact element 131 and can thus identify the respective mating interface 210'.
[0181] Furthermore, when the receptacle unit 2 with the mating interface 210'' is assembled or coupled with the first interface 110, an electrical contact is provided between the second contact element 112 and the second mating contact element 212. In addition, an electrical contact is provided between the mating contact element 211'' and the fourth contact element 133. Thus, when the mating contact element 212 is electrically connected with the mating contact element 211'', an electrical contact is provided between the second contact element 112 and the fourth contact element 133. This electrical contact can be detected and sensed by the electronic circuit 70, which can distinguish between the different electrically coded receptacle units 2, 2', 2'' accordingly.
[0182] 24 is a block diagram of a variant of the injection device 1 described herein, which is provided with an electronic unit 70. In this example, the electronic unit 70 is integrated inside the drug delivery device 1. The electronic unit 70 is located at or near the proximal end of the housing 6.
[0183] The electronic unit 70 comprises a printed circuit board 71 on which a processor 72 is provided. The electronic unit 70 is further provided with a source of electrical energy, typically implemented as a battery 73. The processor 72 and the battery 73 may be provided on opposite sides of the printed circuit board 71.
[0184] The electronic unit 70 further includes an interface 78 electrically connected to at least one of the first and second conductor paths 141, 161. In some examples where the electronic unit 70 is movably disposed within the proximal housing component 14 or connected to a dial extension that is movable relative to the proximal housing component, the interface 78 includes a sliding contact or is connected to the sliding contacts 144, 154, 164, 174, 184, 194. In this manner, the interface 78 and the electronic unit 70 remain in electrical contact with at least one of the interfaces 110, 120.
[0185] The electronic unit 70 may further include a communication interface, for example in the form of a short-range wireless communication interface 76 , which is particularly configured to communicate with a corresponding short-range communication interface 86 of the external electronic device 80 .
[0186] The processor 72 is connected to the locking mechanism 56 and is operable to control the operation of the locking mechanism 56 .
[0187] Optionally, the electronic unit 70 is provided with a sensor 74 operable to detect or measure a movement of at least one movable component of the drive unit 3. The operation of the drive unit 3, and thus of the injection device 1, can be managed and monitored by means of the sensor 74, which may be implemented as one of an optical, capacitive, inductive, optical or acoustic sensor.
[0188] By means of the sensor 74, information regarding the currently set, dialed or dispensed dose size can be obtained and stored in local memory 75. Data captured or acquired during repeated and subsequent uses of the injection device 10 can be stored in the memory 75. Such injection-related data stored in the memory 75 can be synchronized by means of the near-field communications interface 76 with an external electronic device 80 and / or an external database 92, for example, hosted or provided by a healthcare provider.
[0189] Typically, the external electronic device 80 is implemented as a smartphone, as a smartwatch, or as a tablet computer. The external electronic device 80 may include a wide area communication interface 88 for establishing a communication link to an external database 92 via a communication network 90. Typically, the external electronic device 80 is a mobile device or a wearable device. The external electronic device 80 includes a display 81 and / or a speaker 82 for communicating with a user.
[0190] The external electronic device 80 may be wirelessly paired with the electronic unit 70. When pairing is successful, a respective confirmation may be provided to the user, e.g. via a display 81 and / or via a speaker 82 of the external electronic device 80. When data or information is transferred between the electronic unit 70 and the external electronic device 80, a visual and / or audible confirmation may be provided to the user, e.g. by the electronic unit 70 and / or by the external electronic device 80.
[0191] The processor 72 may be configured to perform an automatic relocking, for example, after the end of each dose or in an injection procedure. Furthermore, based on a signal obtainable from the sensor 74, the processor 72 may be provided with information indicative of the remaining fill level of the medicament container 16. Thus, the processor 72 may cause the activation of the interlock 56 or may prevent the unlocking of the interlock 56 when the sensor 74 provides a respective sensor signal that the medicament container 16 is substantially depleted or empty. Uncoupling or recoupling of the container unit 2 together with removal of the medicament container 16 or insertion of the medicament container 16 may trigger an automated locking or disabling of the functions of the drive unit 3 for setting a dose and / or for dispensing a dose.
[0192] 6, operation of the drug delivery devices described herein may begin at time t1, where the protective cap 14 may be removed from the respective drug delivery device. Such removal may be detected by the electronic control unit, for example, when electrical contact between the second interface 120 and the mating interface 220 is disabled.
[0193] At time t2, the electronic unit 70 may be configured to perform a cartridge holder detection routine, in which the signal or electrical contact provided by the first and / or second electrical contact elements 111, 112 is evaluated by the electronic unit 70.
[0194] If the correct receptacle unit 2 or cartridge holder 15 is detected, the electronic unit 70 may switch to an activation mode. If an incorrect cartridge holder 15 or no cartridge holder is detected, the electronic unit 70 may be operable to generate a warning signal or to lock operation of the drive unit 3 by activating an interlock 56 as provided by the electromechanical actuator 50.
[0195] An electronic unit 70 in the dose button 13 can evaluate an electrical signal from or induced by the cartridge holder 15 and can thus unlock the drive unit 3 if the correct or intended cartridge holder or container unit 2 is present. Verification of the correct container unit is provided based on an electrically detectable coding of the cartridge holder 15. In addition, at time t3 a user verification or authentication procedure may also take place, for example by means of a wireless communication link with an external electronic device 80.
[0196] If all these requests are approved and the locking mechanism 56 of the drive unit 3 provided by the electromechanical actuator 50 is locked, the electronic unit 70 can generate an unlock control signal and send the respective unlock or control signal via the first and second electrical control paths 181, 191, thereby unlocking the drive unit 3.
[0197] As mentioned above, the control paths 181, 191 may coincide with or be electrically connected to the conductor paths 141, 151. Thus, actuation of the electromechanical actuator 50 may only require application of an increased voltage or current to activate or switch the electromagnet 52. Then, at time t5, the user sets the appropriate size dose, and at time t6, the user can perform the respective injection procedure. At the end of the injection, therefore at time t7, the interlock of the drive unit 3 can be activated again, for example by changing the control signal from the electronic unit 70. At time t8, the reattachment of the protective cap 14 can be detected.
[0198] In fact, the total number of conductive paths can be reduced by using only one common electrical circuit for the cartridge holder detection signal and for the control signal to activate the electromechanical actuator 50. As shown in Fig. 6, the device 1 can be woken up by removing the protective cap 14. First, a fairly low voltage signal is applied to the first and second conductor paths 141, 151, e.g. for cartridge holder detection purposes and / or for communication with an external electronic device 80. After confirmation of the cartridge holder 15 and / or after authentication of the user, a high (or relatively high) voltage signal is applied to unlock the device.
[0199] As further shown in the block diagram of Fig. 33, the power delivery device 300 includes a printed circuit board 251 having a logic circuit 255. The logic circuit 255 may include a processor 256, a timer 257, and possibly a communication interface 258. The communication interface 258 may be implemented as a wireless communication interface configured to wirelessly communicate with the external electronic device 80 shown in Fig. 24. Thus, the communication interface 258 may be implemented in accordance with a commercially available wireless communication standard such as Bluetooth, Wi-Fi, UWB, or NFC.
[0200] The power supply device 300 can be implemented as a kind of power bank. The power supply device 300 is removably connectable to the body 10, 11 and / or to the housing 6 of the drug delivery device 1. The logic circuit 255 includes a signal generator 254, which is operable to generate a time-out warning signal and / or to generate an energy depletion warning signal. The signal generator 254 is implemented and / or configured to generate at least one of a visual signal, an audio signal, and / or a vibration or tactilely perceptible signal.
[0201] The logic circuit 255 may be operable to detect an electrical connection between the power interface 310 and the electrical interface 130 of the drug delivery device 1. When the mutual electrical connection between the electrical interface 130 and the power interface 310 becomes invalid, for example due to removal of the protective cap 14, the processor 258 may be operable to start the timer 257. The processor 256 is further operable to stop the timer 257 in response to detecting an electrical reconnection or recoupling of the power interface 310 and the electrical interface 130. When started, the timer begins counting in discrete steps, thereby increasing the count value for each time interval.
[0202] When reattachment of the power supply device 300 to the drug delivery device 1 is detected, the processor may be operable to stop the timer 257 and reset the timer 257 if the count value of the previously started timer falls below a predetermined maximum count value.
[0203] In the situation where the user does not reattach the protective cap 14, and thus the power supply device 300, to the drug delivery device 1 within the predetermined period of time, the timer 257 continues to count and the count value may exceed a predetermined maximum count value. The processor 256 is then operable to cause the signal generator 254 to generate a time-out warning signal. Such a warning signal is generated when the timer's count value exceeds the predetermined maximum count value. This may occur if the protective cap 14 has been removed from the drug delivery device 1 for a relatively long period of time. The time-out warning signal prompts the user to return the protective cap 14 to the drug delivery device 1.
[0204] Similarly, the processor 256 may be operable to determine and / or measure a charge level of the rechargeable energy reservoir 250, where the processor 256 is operable to cause the signal generator 254 to generate an energy depletion warning signal when the charge level falls below a predetermined minimum charge threshold. The energy depletion warning signal is at least one of an acoustic signal, an optical or visual signal, and a tactile signal.
[0205] In addition to or instead of generating an alert signal directly perceptible by the user of the device, the respective alert or alert signal may be wirelessly transmitted to the external electronic device 80 via the communications interface 258. A speaker, display or vibration module of the external electronic device may then be operable to generate the alert signal perceptible by the user.
[0206] The flow chart shows in a schematic manner one example of the functionality of the power supply device 300. In a first step 500, the user removes the protective cap 14 from the drug delivery device 1. This removal is detected by the logic circuit 255. Thus, when the removal of the protective cap is detected, in step 502, the timer 257 is started or initiated. In a loop of steps 504, 510, it is checked whether the protective cap is replaced. If in step 504 the cap is replaced, the method proceeds to step 510, where the timer is stopped and possibly reset.
[0207] If, in step 504, reattachment of the cap is not detected, then in step 506 it is checked whether the instantaneous count value of the timer is below a predefined threshold. As long as the timer value is below the threshold, the method returns to step 504. If the timer is equal to or greater than the maximum count value and therefore exceeds the timer threshold, then in step 508 an alert is generated, i.e. a timeout alert.
[0208] In a further flow chart showing another function of the power supply device 300 of FIG. 35, in a first step 600, the protective cap 14 and therefore the power supply device 300 are removed from the drug delivery device 1. In a following step 602, the charge level of the rechargeable energy reservoir 250 is measured or determined. In step 604, the measured energy level is compared with a predetermined minimum charge level. If the measured charge level is below or has fallen below the predetermined minimum charge level, the procedure proceeds to step 606. There, in step 606, an energy depletion warning signal is generated. If, instead, in step 604, the energy level is above the predetermined minimum charge threshold, the method proceeds to step 608, where, when reattached to the drug delivery device and when the power supply interface 310 is properly electrically connected to the electrical interface 130 of the drug delivery device 1, the electrical energy supply device can operate in normal mode and can charge the battery 73 of the electronic unit 70. [Explanation of symbols]
[0209] 1. Drug Delivery Devices 2 Container unit 3 Drive unit 4 Distal end 5 Proximal end 6. Housing 7 Connecting Interface 8 Connection Interface 9 Drive unit housing 10 Inner body 11 Outer body 12. Windows 13 Dose button 14 Protective cap 15 Cartridge holder 16 Drug containers 17 Stopper 18 Syringe needle 20 Distal Drive Sleeve 21 Proximal Drive Sleeve 22 Drive sleeve coupler 23 Distal Clicker 24 Proximal Clicker 25 Clutch spring 26 Number Sleeve 27 Dial Sleeve 28 Clutch 29 Plunger rod 30 Final Dose Nut 40 Device Components 41 Side wall 42 Exterior 43 Inside 44 Longitudinal end face 45 Longitudinal end face 46 Threaded Section 50 Actuator 51 Magnet 52 Magnet 53 Protrusion 54 Recess 55 Bending Arm 56 Locking mechanism 60 Device Components 61 Side wall 62 Exterior 63 Inside 64 Longitudinal end 65 Longitudinal end 66 Threaded Section 70 Electronic Unit 71 Printed Circuit Board 72 processors 73 Batteries 74 Sensors 75 Storage device 76 Communication Interface 78 Interface 80 External Electronic Devices 81 Display 82 Speaker 86 Communication Interface 88 Communication Interface 90 Network 92 Database 110 Interface 111 Contact element 112 Contact element 114 Fasteners 115 Electrical Connectors 116 Contact spring 117 Contact elements 118 Contact element 119 Career 120 Interface 121 Power contact 122 Power contacts 124 Fasteners 125 Snap Elements 126 Protrusion 127 Recess 130 Electrical Interface 131 Contact elements 132 Conductor Path 133 Contact elements 134 Conductor Path 141 Conductor Path 142 Distal end 143 Proximal end 144 Sliding Contact 145 Conductor path extension 146 Contact conductor 151 Conductor Path 152 Distal end 153 Proximal end 154 Sliding contact 155 Conductor path extension 156 Contact conductor 157 Conductor branch 161 Power Path 162 Distal end 163 Proximal end 164 Sliding Contact 165 Power supply path extension 166 Contact Conductor 171 Power Path 172 Distal end 173 Proximal end 174 Sliding Contact 175 Power supply path extension 176 Contact Conductor 181 Control Path 182 Distal end 183 Proximal end 184 Sliding Contact 185 Control Path Extension 191 Control Path 192 Distal end 193 Proximal end 194 Sliding Contact 195 Control Path Extension 210 Counterpart Interface 211 Counterpart contact element 212 Counterpart contact element 214 Counterparty fasteners 215 Contact conductor 220 Counterpart Interface 221 Counterpart power contact 222 Counterpart power contact 224 Counterparty fasteners 225 Opponent Snap Elements 226 Recess 227 Protrusion 240 Cap body 241 Side wall 242 Distal end 243 Proximal end 250 Energy Reservoir 251 Printed Circuit Board 252 Power Connector 254 Signal Generator 255 Logic Circuit 256 processors 257 Timer 258 Communication Interface 261 Power Path 262 Distal end 263 Proximal end 271 Power Path 272 Distal end 273 Proximal end 300 Power Supply Device 310 Power Interface 320 Charging Interface 322 Socket 324 Dielectric Coupler 400 External power supply 421 Cable 422 Counterpart plug 424 Dielectric Coupler
Claims
1. A power supply device (300) for an electronic unit (70) of a drug delivery device (1), comprising: a body (240) extending along a longitudinal direction (A) and including a distal end (242) and a proximal end (243); a rechargeable energy reservoir (250) disposed within or on the body (240); a power interface (310) electrically connected to the rechargeable energy reservoir (250), the power interface (310) being configured to electrically couple with an electrical interface (130) of the drug delivery device (1), the electrical interface (130) being electrically connected to an electronic unit (70), the power interface (310) being operable to transfer electrical energy from the rechargeable energy reservoir (250) to the electronic unit (70) via the electrical interface (130); a charging interface (320) electrically connected to the rechargeable energy reservoir (250) and operable to connect to an external power source (400) for charging the rechargeable energy reservoir (250); The power supply device comprising:
2. The power delivery device (300) of claim 1, wherein the charging interface (320) comprises a power connector (252).
3. 3. The power supply device (300) of claim 1 or 2, wherein the rechargeable energy reservoir (250) is disposed inside the body (240), the power supply interface (310) is disposed at or extends to the proximal end (243), and the charging interface (320) is disposed at the distal end (242).
4. A power supply device (300) as described in any one of claims 1 to 3, wherein the body (240) includes a mechanical mating interface (220) at a proximal end (243) for removably fastening the body (240) to a complementary shaped mechanical interface (120) of the drug delivery device (1).
5. The power delivery device (300) of claim 4, wherein the mechanical mating interface (220) includes a mating fastener (224) that releasably engages a complementary fastener (124) provided on the mechanical interface (120).
6. The power supply device (300) according to any one of claims 1 to 5, wherein the body (240) includes a side wall (241) limiting the extent of a receptacle (244), the receptacle being open in a proximal direction to receive at least a portion of the drug delivery device (1).
7. The power supply device (300) according to claim 5 or 6, wherein the mechanical counter interface (220) is integrated into or provided at a proximal end of the side wall (241).
8. The power interface (310): a first power conductor path (261) electrically connecting the power interface (310) to a rechargeable energy reservoir (250); a second power conductor path (271) isolated from the first power conductor path (261) and electrically connecting the power interface (310) to the rechargeable energy reservoir (250); The power supply device (300) of any one of claims 1 to 7, comprising:
9. 8. The power supply device (300) of claim 5 or 7, wherein at least one of the first power supply conductor path (261) and the second power supply conductor path (271) is arranged on an inner surface (245) or on an outer surface (246) of the side wall (241).
10. The power interface (310): a first mating power contact (221) electrically connected to the rechargeable energy reservoir (250) and electrically connectable to a complementarily shaped first power contact (121) of the drug delivery device (1); a second mating power contact (222) electrically connected to the rechargeable energy reservoir (250) and electrically connectable to a complementary shaped second power contact (122) of the drug delivery device (1); The power supply device (300) of any one of claims 1 to 9, comprising:
11. The power supply device (300) according to claim 4 or 10, wherein the first mating power contact (221) and the second mating power contact (222) are disposed on or integrated into the mechanical mating interface (220).
12. The power supply device (300) according to claim 5 or 10, wherein the first mating power contact (221) and the second mating power contact (222) are integrated into a mating fastener (224).
13. The power supply device (300) according to any one of claims 10 to 12, wherein the first mating power contact (221) and the second mating power contact (222) are disposed at a proximal end (243) of the body (240).
14. The battery further includes a logic circuit (255) including a processor (256) coupled to the rechargeable energy reservoir (250) and coupled to at least one of the power interface (310) and the charging interface (320), the processor (256) being configured to: Charging the rechargeable energy reservoir (250) via the charging interface (320); and Providing electrical energy to the drug delivery device (1) via a power interface (310) The power supply device (300) of any one of claims 1 to 13, operable to control at least one of:
15. The method further includes a timer (257) and a signal generator (254) controllable by a processor (256), the processor (256) comprising: initiating a timer (257) in response to detecting an electrical disconnection of the power interface (310) from the electronic unit (70) of the drug delivery device (1); in response to detecting an electrical reconnection of the power interface (310) to the electronic unit (70) of the drug delivery device (1), stopping the timer (257); When the count value of the timer (257) exceeds a predetermined maximum count value, the signal generator (254) generates a time-out warning signal. The power supply device (300) of claim 14, operable to:
16. 16. The power supply device (300) of claim 14 or 15, wherein the processor (256) is operable to determine a charge level of the rechargeable energy reservoir (250), and the processor (256) is operable to cause the signal generator (254) to generate an energy depletion warning signal when the charge level falls below a predetermined minimum charge threshold.
17. A power supply device (300) according to any one of the preceding claims, comprising a protective cap (14) or implemented as a protective cap (14) of a drug delivery device implemented as a handheld injection device.
18. A drug delivery device (1) configured for setting and dispensing a dose of a medicament, comprising: A housing (6); an electronic unit (70) disposed on or within said housing (6); an electrical interface (130) on or within the housing (6) electrically connected to the electronic unit (70) and configured to electrically couple to a power supply interface (310) of a power supply device (300) according to any one of claims 1 to 17; The drug delivery device comprising:
19. A mechanical interface (120); A power supply device (300) according to any one of claims 1 to 17, 20. The drug delivery device (1) of claim 18, further comprising a power supply device (300) comprising a mechanical counter interface (220) removably fastened to the mechanical interface (120).
Citation Information
Patent Citations
Medical assembly with monitoring device
JP2012504440A
Replaceable cap for administration device
JP2013530004A
Motorized drug delivery device with charging safety features
JP2017501792A
Pressure-based Event Detection
JP2018519938A
injection device
JP2020501657A
